INmune Bio Inc (INMB) concluded trading on Wednesday at a closing price of $2.86, with 5.62 million shares of worth about $16.06 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -56.17% during that period and on July 23, 2025 the price saw a gain of about 19.17%. Currently the company’s common shares owned by public are about 22.93M shares, out of which, 18.90M shares are available for trading.
Stock saw a price change of 22.22% in past 5 days and over the past one month there was a price change of -54.02%. Year-to-date (YTD), INMB shares are showing a performance of -64.60% which decreased to -38.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.89 but also hit the highest price of $11.64 during that period. The average intraday trading volume for INmune Bio Inc shares is 2.61 million. The stock is currently trading -2.39% below its 20-day simple moving average (SMA20), while that difference is down -49.29% for SMA50 and it goes to -55.71% lower than SMA200.
INmune Bio Inc (NASDAQ: INMB) currently have 22.93M outstanding shares and institutions hold larger chunk of about 27.95% of that.
The stock has a current market capitalization of $76.03M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$1.95 in the same period. It has Quick Ratio of 2.64 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INMB, volatility over the week remained 11.43% while standing at 18.54% over the month.
Stock’s fiscal year EPS is expected to rise by 30.94% while it is estimated to increase by 9.71% in next year. EPS is likely to grow at an annualized rate of 47.53% for next 5-years, compared to annual growth of -23.07% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on July 01, 2025 offering a Sector underperform rating for the stock and assigned a target price of $0.60 to it. On January 28, 2025, Rodman & Renshaw Initiated their recommendations, while on October 21, 2024, Alliance Global Partners Initiated their ratings for the stock with a price target of $20. Stock get an Outperform rating from Raymond James on September 27, 2024.
